Taken together, our in vitro, in vivo and clinical data support an important role for the MEK5–ERK5 signalling pathway in invasive PCa and may represent a potential target for therapy, including primary and metastatic PCa. This evidence concerns the gene MAP2K5 and posterior cortical atrophy.